Your Article Summary
Effect of Age on Survival Benefit of Adjuvant Chemotherapy in Elderly Patients with Stage III Colon Cancer
Journal of the American Geriatrics Society, 06/29/09
Zuckerman IH et al. - These findings have important clinical and policy implications for the risk–benefit calculation induced by treatment in older patients with Stage III colon cancer. The results suggest that there is a benefit from chemotherapy, but the benefit is lower with older age.
Related Articles
Large age and hospital-dependent variation in administration of adjuvant chemotherapy for stage III colon cancer in southern Netherlands
Annals of Oncology, 11/04/09
Relevance Score: 97%
Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin
Annals of Oncology, 10/19/09
Relevance Score: 97%
Nodal staging score: A tool to assess adequate staging of node-negative colon cancer
Journal of Clinical Oncology, 11/16/09
Relevance Score: 96%
Radiochemotherapy in the elderly with lung cancer
Expert Review of Anticancer Therapy, 10/22/09
Relevance Score: 96%
Original contribution: association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen
JAMA, 10/07/09
Relevance Score: 94%
Today in Colorectal Cancer/Polyps...keeping you current
Receive free subspecialty "5-minute updates" via email
Long-term outcomes after hepatic resection for colorectal metastases in young patients
Cancer, 12/14/09
Distinct features of colorectal cancer in children and adolescents
Cancer, 12/14/09
Vascular Endothelial Growth Factor Plus Epidermal Growth Factor Receptor Dual Targeted Therapy in Metastatic Colorectal Cancer: Synergy or Antagonism
Journal of Oncology, 12/14/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Intensive chemotherapy improves survival in pediatric high-grade glioma after gross total resection: results of the HIT-GBM-C protocol
Cancer, 12/14/09
The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkins lymphoma
European Journal of Haematology, 12/14/09

See Latest Articles